SCHEMBL15601966

SCHEMBL15601966

Cc1cccc2c(C(C)(C)C)c[nH]c12

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.51
TRIM33 Q9UPN9 1/20 0.51
BRPF1 P55201 1/20 0.50
HTR2A P28223 1/20 0.49
MAPT P10636 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
NR4A2 P43354 1/20 0.46
SOS2 Q07890 1/20 0.46
AR P10275 7/20 0.44
GABRA1 P14867 1/20 0.42
GABRB2 P47870 1/20 0.42
AHR P35869 1/20 0.41
KIF11 P52732 2/20 0.41
CYP1A2 P05177 1/20 0.39
CYP2A6 P11509 1/20 0.39
PCSK9 Q8NBP7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15591975 0.84 KIF11 (0.52) TRIM24TRIM33BRPF1HTR2ASMN1; SMN2
SCHEMBL25034434 0.79 DYRK1A (0.50) ARAHRKIF11
SCHEMBL19104233 0.79 GPR84 (0.53) ARKIF11PCSK9
SCHEMBL23479616 0.79 DYRK1A (0.50) HTR2ANR4A2ARAHRKIF11
SCHEMBL27876976 0.79 TRIM24 (0.54) TRIM24TRIM33BRPF1HTR2AMAPT
SCHEMBL27609949 0.78 BRPF1 (0.47) TRIM24TRIM33BRPF1HTR2AMAPT
SCHEMBL31607554 0.77 TRIM24 (0.60) TRIM24TRIM33BRPF1HTR2AMAPT
SCHEMBL2143637 0.77 TRIM24 (0.60) TRIM24TRIM33BRPF1HTR2AMAPT
SCHEMBL14667571 0.77 ALDH1A1 (0.53) MAPTGABRA1GABRB2
SCHEMBL23102840 0.77 HTR2A (0.53) HTR2AMAPTSMN1; SMN2AR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030853-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2024-07-09 US disclosed
US-12030853-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2024-07-09 US disclosed
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF SCHRÖDINGER, INC. 2024-01-25 US disclosed
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2023-01-26 US disclosed
US-11358969-B2 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2022-06-14 US disclosed
US-20210171461-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2021-06-10 US disclosed
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF PAHR THERAPEUTICS, INC. 2020-10-22 US disclosed
US-10689388-B1 Indole AHR inhibitors and uses thereof Ikena Oncology, Inc. (US) 2020-06-23 US disclosed
US-10570138-B2 Indole AHR inhibitors and uses thereof KYN THERAPEUTICS (US) 2020-02-25 US disclosed
US-9284296-B2 Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions AUBERGINE PHARMACEUTICALS LLC (US) 2016-03-15 US disclosed
US-8952050-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-02-10 US disclosed
US-20140080826-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-03-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10570138-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 TRIM24 1061/4885TRIM33 1844/4885BRPF1 2954/4885
US-20140080826-A1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS CFTR, ABCB1, ABCC2 TRIM24 3587/4885TRIM33 2781/4885BRPF1 932/4885
US-11358969-B2 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 TRIM24 1061/4885TRIM33 1844/4885BRPF1 2954/4885
US-20200331917-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 TRIM24 1061/4885TRIM33 1844/4885BRPF1 2954/4885
US-10689388-B1 Indole AHR inhibitors and uses thereof AHR, ARNT, IDO1 TRIM24 1061/4885TRIM33 1844/4885BRPF1 2954/4885
US-20230028336-A1 INDOLE AHR INHIBITORS AND USES THEREOF AHR, ARNT, IDO1 TRIM24 1061/4885TRIM33 1844/4885BRPF1 2954/4885
US-20240025898-A1 HPK1 ANTAGONISTS AND USES THEREOF PDXK, HIPK1, PCK1 TRIM24 2780/4885TRIM33 3767/4885BRPF1 2221/4885
US-12030853-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 TRIM24 1440/4885TRIM33 2245/4885BRPF1 621/4885
US-20210171461-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 TRIM24 1440/4885TRIM33 2245/4885BRPF1 621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.